Omeros Company Profile (NASDAQ:OMER)

About Omeros (NASDAQ:OMER)

Omeros logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:OMER
  • CUSIP: 68214310
  • Web:
  • Market Cap: $689.84 million
  • Outstanding Shares: 43,939,000
Average Prices:
  • 50 Day Moving Avg: $15.91
  • 200 Day Moving Avg: $12.44
  • 52 Week Range: $7.20 - $17.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -92.35
  • P/E Growth: -0.15
Sales & Book Value:
  • Annual Revenue: $46.46 million
  • Price / Sales: 14.85
  • Book Value: ($1.10) per share
  • Price / Book: -14.27
  • EBIDTA: ($47,190,000.00)
  • Net Margins: -189.16%
  • Return on Assets: -104.29%
  • Debt-to-Equity Ratio: -3.09%
  • Current Ratio: 3.78%
  • Quick Ratio: 3.69%
  • Average Volume: 644,433 shs.
  • Beta: 3.16
  • Short Ratio: 10.15

Frequently Asked Questions for Omeros (NASDAQ:OMER)

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.01. The company earned $12.26 million during the quarter, compared to analyst estimates of $13.32 million. The business's revenue for the quarter was up 65.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.54) earnings per share. View Omeros' Earnings History.

Where is Omeros' stock going? Where will Omeros' stock price be in 2017?

7 analysts have issued 1-year target prices for Omeros' shares. Their forecasts range from $8.63 to $75.00. On average, they anticipate Omeros' stock price to reach $32.66 in the next year. View Analyst Ratings for Omeros.

What are analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:

  • 1. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)
  • 2. Maxim Group analysts commented, "Omeros announced a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and transfusion-dependent adolescent girl who was treated with OMS721 under a compassionate-use protocol. The presentation 'Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient' occurred at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation in Marseille, France on Monday, March 27, 2017. OMS721 continues to demonstrate positive data across multiple indications that are associated with complement. What differentiates OMS721 from other complement inhibitors like Alexion's Soliris, is the ability to target just a single arm of the complement system (lectin pathway) which leaves the rest of the system intact for important functions like protecting against infections." (3/27/2017)
  • 3. Cantor Fitzgerald analysts commented, "We are reiterating our Overweight rating and $21 price target, following Omeros' 4Q16 earnings call. Omeros achieved stable revenue growth in 4Q16, with sales of $12.9 million compared with FactSet's consensus estimate of $12.6 million. While sales have demonstrated strong linear growth, we are adjusting our estimates for revenue sales in 2017 (FY estimate of $68 million, previously $87 million) and slightly prolonging the ramp to peak market penetration by one year to 2023 (previously 2022). Fundamentally, we are encouraged by the progress Omeros has made with educating physicians, pharmacists and payors, and we remain focused on signs for a potential inflection point in sales. Omeros also provided an update on its clinical pipeline, which could initiate Phase 3 development across three indications." (3/17/2017)
  • 4. Needham & Company LLC analysts commented, "OMER's 4Q16 results, driven by Omidria sales that slightly bested consensus, came slightly ahead of Street expectations. Omidria sales are now annualizing at ~$52MM, which gives us confidence that sales can ramp up to the mid-$60MM range in 2017. Our concern with Omidria rests with the transitional passthrough reimbursement that potentially expires on 1/1/2018. If reimbursement is not extended, Omidria will likely be reimbursed as part of a procedural bundled payment, which would likely impact its current price. On the pipeline front, the OMS721 ph 3 trial for aHUS is now open for enrollment. We continue to view the pipeline (esp. OMS721) as a key value growth driver for OMER, though one that requires additional clinical data for validation. We maintain our Buy rating and adjust our PT to $22 (from $24)." (3/17/2017)
  • 5. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (3/15/2017)

Who are some of Omeros' key competitors?

Who owns Omeros stock?

Omeros' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (11.62%), Vanguard Group Inc. (3.95%), State Street Corp (2.09%), American Financial Group Inc. (1.63%), Tocqueville Asset Management L.P. (1.54%) and UBS Group AG (0.91%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Peter A Md Demopulos and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Who sold Omeros stock? Who is selling Omeros stock?

Omeros' stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Stifel Financial Corp, Rubric Capital Management LP, Ingalls & Snyder LLC, TIAA CREF Investment Management LLC, State Street Corp, Stoneridge Investment Partners LLC and Wedbush Securities Inc.. Company insiders that have sold Omeros stock in the last year include Gregory A Md Demopulos, Marcia S Kelbon and Thomas J Cable. View Insider Buying and Selling for Omeros.

Who bought Omeros stock? Who is buying Omeros stock?

Omeros' stock was purchased by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC, Vanguard Group Inc., Chicago Equity Partners LLC, Morgan Stanley, Geode Capital Management LLC, Candriam Luxembourg S.C.A., Parametric Portfolio Associates LLC and Highbridge Capital Management LLC. View Insider Buying and Selling for Omeros.

How do I buy Omeros stock?

Shares of Omeros can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Omeros stock cost?

One share of Omeros stock can currently be purchased for approximately $15.70.

Analyst Ratings

Consensus Ratings for Omeros (NASDAQ:OMER) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $32.66 (108.03% upside)

Analysts' Ratings History for Omeros (NASDAQ:OMER)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Maxim GroupSet Price TargetBuy$22.00 -> $23.00LowView Rating Details
5/10/2017WedbushReiterated RatingOutperform$47.00LowView Rating Details
5/11/2017Cantor FitzgeraldDowngradeBuy -> Neutral$21.00 -> $15.00HighView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/30/2017WBB SecuritiesReiterated RatingBuy$75.00MediumView Rating Details
3/20/2017Cowen and CompanyReiterated RatingOutperformHighView Rating Details
3/17/2017Needham & Company LLCReiterated RatingBuy -> Buy$24.00 -> $22.00HighView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
8/19/2015Roth CapitalReiterated RatingBuy$38.00N/AView Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$38.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Omeros (NASDAQ:OMER)
Earnings by Quarter for Omeros (NASDAQ:OMER)
Earnings History by Quarter for Omeros (NASDAQ:OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omeros (NASDAQ:OMER)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: $0.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.34)($0.35)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.29)($0.21)($0.25)
Q4 20172($0.28)($0.12)($0.20)
Q1 20181($0.02)($0.02)($0.02)
Q2 20181$0.09$0.09$0.09
Q3 20181$0.16$0.16$0.16
Q4 20181$0.24$0.24$0.24
(Data provided by Zacks Investment Research)


Dividend History for Omeros (NASDAQ:OMER)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Omeros (NASDAQ:OMER)
Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 47.94%
Insider Trades by Quarter for Omeros (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)
Insider Trades by Quarter for Omeros (NASDAQ:OMER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.00View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.84View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.00View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.40View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.60View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Omeros (NASDAQ:OMER)
Latest Headlines for Omeros (NASDAQ:OMER)
DateHeadline logoETFs with exposure to Omeros Corp. : May 22, 2017 - May 22 at 6:14 PM logoOmeros Co. (OMER) Given "Buy" Rating at Maxim Group - May 22 at 10:54 AM logoOmeros Co. (OMER) Given Consensus Recommendation of "Buy" by Brokerages - May 19 at 5:08 PM logoOmeros Corp. :OMER-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 11:48 AM logoOmeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial - May 17 at 8:41 AM logoEdited Transcript of OMER earnings conference call or presentation 10-May-17 8:30pm GMT - May 16 at 6:44 PM logo3 Biotech Stocks I'd Buy Right Now - May 15 at 6:18 PM logoWedbush Comments on Omeros Co.'s Q2 2017 Earnings (OMER) - May 15 at 7:30 AM logoCantor Fitzgerald Lowers Omeros Co. (OMER) to Neutral - May 14 at 8:45 AM logoMaxim Group Analysts Give Omeros Co. (OMER) a $23.00 Price Target - May 13 at 6:26 PM logoWedbush Weighs in on Omeros Co.'s Q1 2018 Earnings (OMER) - May 12 at 4:08 PM logoHere's Why Omeros Corporation Stock Is Falling Today - May 11 at 7:29 PM logoOmeros Co. (OMER) Receives "Buy" Rating from Wedbush - May 11 at 4:20 PM logoHere's Why Omeros Corporation Stock Is Falling Today - May 11 at 1:17 PM logoOmeros Co. (OMER) Announces Earnings Results - May 10 at 11:48 PM logoOmeros Corporation Reports First Quarter 2017 Financial Results - May 10 at 7:15 PM logoOmeros reports 1Q loss - May 10 at 7:15 PM logoInvestor Network: Omeros Corporation to Host Earnings Call - May 10 at 11:52 AM logoOmeros Co. (OMER) Expected to Announce Earnings of -$0.34 Per Share - May 9 at 8:08 AM logoSomewhat Positive News Coverage Somewhat Likely to Affect Omeros (OMER) Stock Price - May 4 at 9:34 PM logoOmeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017 - May 3 at 8:01 PM logoOmeros (OMER) Receiving Somewhat Favorable Media Coverage, Analysis Shows - May 1 at 7:00 PM logoOmeros (OMER) Earning Somewhat Favorable News Coverage, AlphaOne Reports - April 28 at 10:06 PM logoSomewhat Favorable Media Coverage Unlikely to Impact Omeros (OMER) Share Price - April 24 at 8:58 PM logoOmeros Co. (OMER) Receives Consensus Recommendation of "Buy" from Brokerages - April 24 at 6:16 PM logoOmeros Co. (OMER) Expected to Announce Quarterly Sales of $13.32 Million - April 20 at 2:42 PM logo-$0.34 EPS Expected for Omeros Co. (OMER) This Quarter - April 18 at 8:12 AM logoOmeros (OMER) Earning Positive News Coverage, Study Finds - April 17 at 1:24 PM logoInsider Selling: Omeros Co. (OMER) Director Sells 3,000 Shares of Stock - April 14 at 4:56 PM logoOmeros (OMER) Receiving Favorable Media Coverage, Report Finds - April 13 at 8:38 PM logoOmeros Co. (OMER) Given "Buy" Rating at WBB Securities - April 5 at 9:01 AM logoOmeros Co. (OMER) Stock Rating Reaffirmed by Wedbush - April 3 at 11:31 AM logoOmeros to Present at the Needham Healthcare Conference - April 3 at 9:31 AM logoOmeros' (OMER) "Buy" Rating Reaffirmed at FBR & Co - April 2 at 11:30 PM logoOmeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases - March 30 at 7:20 PM logoOmeros Co. (OMER) Earns Buy Rating from WBB Securities - March 30 at 4:31 PM logoOsiris Therapeutics Sees Stock Bounce Up On Restatement, Omeros Readies for Presentations of its OMR-721 Candidate Drug - March 29 at 7:45 PM logoTop Biotech Stocks for Growth Investors - March 29 at 4:24 PM logoHere's Why Omeros Corporation Stock Climbed Higher Today - March 28 at 5:55 PM logoOmeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation - March 28 at 9:55 AM logoOmeros Co. (OMER) Given a $22.00 Price Target by Maxim Group Analysts - March 27 at 2:49 PM logoOmeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology - March 27 at 9:56 AM logoOMEROS CORP Financials - March 23 at 7:31 PM logoCantor Fitzgerald Brokers Cut Earnings Estimates for Omeros Co. (OMER) - March 23 at 10:17 AM logoWedbush Analysts Increase Earnings Estimates for Omeros Co. (OMER) - March 22 at 9:50 AM logoFY2021 EPS Estimates for Omeros Co. (OMER) Lowered by Analyst - March 21 at 12:22 PM logoOmeros and Keryx are Potential Beneficiaries of New Administration Deregulation - March 21 at 11:16 AM logoOmeros Co. (OMER) Lifted to Hold at Zacks Investment Research - March 21 at 7:41 AM logoOmeros Co. (OMER) Earns Outperform Rating from Cowen and Company - March 20 at 9:13 PM logoFY2020 EPS Estimates for Omeros Co. Reduced by Analyst (OMER) - March 20 at 12:19 PM



Omeros (OMER) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff